

# Michigan Medicine Annual Hematologic Malignancies Symposium 2025

**Saturday, October 11, 2025**

**9:00am – 3:30pm**  
(Check-in and Breakfast at 8:30 a.m.)


**Kensington Court Hotel and  
Conference Center, 3500 S State St,  
Ann Arbor, MI 48108**

Register at:  
<https://michmed.org/y5gWq>



**CME accredited**

**This symposium is intended for  
physicians, physicians in training  
(residents/fellows), pharmacists,  
and advanced practice providers in  
the field of malignant hematology.**



**Jennifer Woyach, MD**  
Professor and Director of the Division  
of Hematology, D. Warren Brown Chair  
of Leukemia Research and co-Director  
of the Leukemia Research Program,  
The OSU Comprehensive Cancer  
Center

## MORNING SESSIONS

8:30-9:00 **Registration and Breakfast**

9:00-11:30 **Two Concurrent Sessions (A&B)**

### SESSION A - Lymphoma I - CARs and Autos

9:00-9:20 **The Witch is Dead... Throwing Water on the Role of Autotransplant in Patients With Mantle Cell Lymphoma**  
**Tycel Phillips, MD**; City of Hope Comprehensive Cancer Center, Los Angeles, CA

9:25-9:45 **CAR T in Non Hodgkins Lymphoma**  
**Monalisa Ghosh, MD**; Michigan Medicine, Division of Hematology/Oncology, Adult Blood and Marrow Transplantation

9:45-10:00 **"Ask the Experts", Drs. Phillips and Ghosh: 10-15 Minutes for Questions/Cases**  
Moderator: **Yasmin Karimi, MD**; Michigan Medicine, Division of Hematology/ Oncology

10:00-10:30 **T-cell Lymphomas: Deconstructing the NCCN Guidelines**  
**Ryan Wilcox, MD, PhD**; Michigan Medicine, Division of Hematology/Oncology; Section Head, Lymphoma and Myeloma

10:30-11:00 **Updates in Hodgkin Lymphoma Treatment and the Role of Radiation**  
**Dahlia Sano, MD**; Michigan Medicine, Division of Hematology/ Oncology  
**Kyle Cuneo, MD**; Michigan Medicine Radiology Oncology

11:00-11:30 **High-risk CLL and Richter's Transformation**  
**Sami Malek, MD**; Michigan Medicine, Division of Hematology/ Oncology

### SESSION B - MDS/AML/MPN/ALL

9:00-10:00 **Clinical Controversies in Acute Leukemia**  
**Patrick Burke, MD**; **Dale Bixby, MD, PhD**; Michigan Medicine, Division of Hematology/Oncology  
**Anthony Perissinotti, PharmD, BCOP**; **Bernie Marini, PharmD, BCOP**; **Lydia Benitz Colon, PharmD, BCOP**; Michigan Medicine, Hematology/Oncology Pharmacy

10:00-10:20 **Update in Myelofibrosis**  
**Moshe Talpaz, MD**; Michigan Medicine, Division of Hematology/ Oncology

10:20-10:50 **Clonal Hematopoiesis**  
**Morgan Jones, MD, PhD**; Michigan Medicine, Division of Hematology/Oncology

10:50-11:20 **ET/PV: New Treatments on the Horizon, But Who Needs Treatment?**  
**Kristen Pettit, MD**; Michigan Medicine, Division of Hematology/ Oncology  
**Victoria Nachar, PharmD, BCOP**; Michigan Medicine Hematology/ Oncology Pharmacy

11:30-12:30 **Lunch Available**

12:00-1:00 **Keynote Address - CLL**  
**Jennifer Woyach, MD**; Professor and Director of the Division of Hematology, D. Warren Brown Chair of Leukemia Research and co-Director of the Leukemia Research Program, The OSU Comprehensive Cancer Center

See reverse side for  
concurrent afternoon sessions



**ROGEL CANCER CENTER**  
UNIVERSITY OF MICHIGAN HEALTH



# Hematologic Malignancies Symposium 2025

## AFTERNOON SESSIONS

1:00-3:30 **Two Concurrent Sessions (A&B)**

### SESSION A - Lymphoma II

1:00-2:00 **Panel Discussion: Audience-Provided Cases/Questions**  
**Yasmin Karimi, MD; Dahlia Sano, MD; Shannon Carty, MD; Jon Weiss, MD;** Michigan Medicine, Division of Hematology/Oncology  
**Tyrel Phillips, MD;** City of Hope Comprehensive Cancer Center, Los Angeles, CA  
**Moderator: Ryan Wilcox, MD, PhD;** Michigan Medicine, Division of Hematology/Oncology

2:00-2:30 **Diffuse Large B-Cell Lymphoma**  
**Yasmin Karimi, MD;** Michigan Medicine, Division of Hematology/Oncology

2:30-3:00 **Immunodeficiency-associated NHL**  
**Shannon Carty, MD;** Michigan Medicine, Division of Hematology/Oncology

3:00-3:30 **Follicular Lymphoma**  
**Jon Weiss, MD;** Michigan Medicine, Division of Hematology/Oncology

### SESSION B - Myeloma

1:00-2:00 **AL Amyloidosis: Beyond ANDROMEDA**  
**Jeff Zonder, MD;** Karmanos Cancer Center, Hematology Oncology Multiple Myeloma and Amyloidosis Program

2:00-2:45 **Where to Park the CAR? Balancing Cell Therapy Response and Toxicity in Multiple Myeloma**  
**Marcus Geer, MD;** Michigan Medicine, Division of Hematology/Oncology

2:45-3:30 **Management of Multiple Myeloma in 2025: State of the Art**  
**Matt Pianko, MD;** Michigan Medicine, Division of Hematology/Oncology

CME accredited

#### Accreditation and Credit Designation

The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Michigan Medical School designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In partnership with:



#### Description with Expected Results

The University of Michigan Rogel Cancer Center (UMRCC) is an NCI-designated comprehensive cancer center with a history of excellence in cancer care, education, and research. The UMRCC catchment area includes the entire State of Michigan, its ~10M residents, and ~750 community medical oncologists. **After completing this activity** participants will be able to utilize current, state of the art updates in the diagnosis, risk stratification, and treatment of all hematologic malignancies, routinely obtain and apply information about clinical trials designed specifically to treat Hematologic Malignancies. They will also be able to enroll patients to the groundbreaking and often lifesaving clinical trials. After completion of this activity, patient outcomes will be improved by having been enrolled in the appropriate clinical trials designed specifically to treat Hematologic Malignancies.

#### Faculty Planner

Ryan Wilcox, MD, PhD  
Department of Internal Medicine,  
Division of Hematology/Oncology  
Section Head, Lymphoma & Myeloma

#### Financial Disclosure Information

Individuals in control of content have no relevant financial relationships with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

No cost to attend.



**ROGEL CANCER CENTER**  
UNIVERSITY OF MICHIGAN HEALTH